Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | BCR | P11274 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3981035 | 0.85 | CHRNA7 (0.55) | CHRNA7ABL1BCR | |
| SCHEMBL3970683 | 0.84 | ABL1 (0.59) | CHRNA7ABL1BCRFAAHEPHX2 | |
| SCHEMBL28758871 | 0.81 | EPHX2 (0.47) | CHRNA7ABL1BCRFAAHEPHX2 | |
| SCHEMBL3977569 | 0.81 | CCNT1 (0.60) | CHRNA7ABL1BCRAURKA | |
| SCHEMBL30568377 | 0.80 | SCN9A (0.61) | CHRNA7ABL1BCRPLK1 | |
| SCHEMBL5473190 | 0.80 | EPHX2 (0.70) | ABL1BCRFAAHEPHX2AURKA | |
| SCHEMBL3904982 | 0.79 | ABL1 (0.82) | ABL1BCR | |
| SCHEMBL20188245 | 0.79 | GSK3A (0.47) | — | |
| SCHEMBL30530318 | 0.79 | GSK3A (0.47) | — | |
| SCHEMBL3397117 | 0.77 | DHODH (0.50) | ABL1BCRFAAHEPHX2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613595-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-01 | — | — | EP | disclosed |
| EP-1613595-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-01-11 | — | — | EP | disclosed |
| US-20050014753-A1 | Novel compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-01-20 | — | — | US | disclosed |
| WO-2004089286-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014753-A1 | Novel compounds and compositions as protein kinase inhibitors | ABL1, BCR, PDGFRA | CHRNA7 4215/4885ABL1 1/4885BCR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.